ProfileGDS5678 / 1451809_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 74% 72% 71% 71% 79% 72% 72% 71% 70% 70% 74% 73% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.7168973
GSM967853U87-EV human glioblastoma xenograft - Control 24.8892374
GSM967854U87-EV human glioblastoma xenograft - Control 34.5843772
GSM967855U87-EV human glioblastoma xenograft - Control 44.5875271
GSM967856U87-EV human glioblastoma xenograft - Control 54.4573271
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.344779
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5522972
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.5783172
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.5092771
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3903970
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.3558570
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8691874
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.719973
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3799270